Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Selenium + tacrolimus is a combination of two agents—selenium, an essential trace mineral with antioxidant properties, and tacrolimus, an immunosuppressive calcineurin inhibitor. This combination has been studied primarily in preclinical and early clinical settings for its potential to mitigate the toxic side effects of tacrolimus (notably oxidative stress and tissue toxicity) or as a topical therapy for inflammatory conditions such as oral lichen planus. Selenium acts by enhancing antioxidant defenses (e.g., increasing heme oxygenase 1 expression), while tacrolimus suppresses immune responses by inhibiting calcineurin-dependent T-cell activation[1][3][4]. The combination is not a standard pharmaceutical product but may be used experimentally or compounded for specific indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on selenium + tacrolimus.